Mounjaro · Zepbound · dual GIP/GLP-1 agonist
Tirzepatide
Label FDA-approved
What it is
Tirzepatide is a single peptide engineered to activate both the GIP and GLP-1 receptors. It is a prescription product with large outcome and obesity programs. Research-chemical “TZ” vials are not Mounjaro or Zepbound.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Approved as Mounjaro / Zepbound. Hits two incretin receptors (GLP-1 and GIP).
- What people feel: less hunger, earlier fullness, slower eating, and often substantial weight and glucose change on the label.
- Studied and approved for type 2 diabetes and chronic weight management — follow those labels if a prescription product is in play.
- Stomach side effects during the climb-up weeks are the main day-to-day tradeoff.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
GLP-1 receptor activity slows gastric emptying, reduces appetite, and supports glucose-dependent insulin secretion. GIP receptor activity adds incretin signaling that, in this molecule, appears to contribute to additional weight and glycemic effect versus GLP-1-only drugs in head-to-heads.
Possible side effects
Label-class effects: nausea, vomiting, diarrhea, constipation, abdominal pain, risk of gallbladder disease, pancreatitis warning language, boxed warning regarding thyroid C-cell tumors in rodents (same family as other GLP-1 RAs), and hypoglycemia when combined with insulin or sulfonylureas. Titration exists specifically to cut GI dropouts.
Protocol ranges
| Source tier | Amount | Cadence | Notes |
|---|---|---|---|
| Label | 2.5 mg weekly | Weeks 1–4 | Start dose; not intended as a long-term therapeutic dose |
| Label | 5, 7.5, 10, 12.5, 15 mg | Increase by 2.5 mg no faster than every 4 weeks | Maintenance selected by tolerability and indication |